RECTAL CANCER OUTCOME MEASUREMENT IN ILLAWARRA SHOALHAVEN LOCAL HEALTH DISTRICT



CLINICIAN INFORMATION SHEET - DATA COLLECTION

The aim of this project is to introduce outcome measurements into routine clinical care for rectal cancer patients in the Illawarra Shoalhaven Local Health District (ISLHD). Outcome measurements allow us to measure the quality of care we provide and identify areas where we can improve.

WHY ARE WE COLLECTING PATIENT OUTCOMES?

We are seeking to answer questions such as:

- How does rectal cancer and its treatments affect our patients' quality of life and daily functioning
- How many rectal patients experience side-effects of treatment
- How do our services and our patient outcomes compare with those around the world

WHAT TOOLS ARE WE USING TO COLLECT PATIENT OUTCOMES?

ISLHD Cancer Services has implemented a comprehensive suite of outcome measures for rectal cancer using the ICHOM (International Consortium for Health Outcomes) framework.



Survival and Disease Control: These are measures which evaluate success against the overall goals of cancer treatment: freedom from recurrence / progression and survival.

Disutility of Care: These measures quantify the short-term complications of treatment. These measures will be collected while the patient is undergoing treatment or within 90 days of starting treatment.

Degree of Health: These measures evaluate the extent to which patients are able to lead productive lives, free of the effects of disease and treatment.

Co-morbidity (note this is not part of the ICHOM standards but clinicians wanted to see how co-morbidities affected outcomes longer-term and how this might inform decision-making at the MDTs).

WHO ARE WE COLLECTING PATIENT OUTCOMES FROM?

All current and future rectal cancer patients.

HOW ARE WE COLLECTING PATIENT OUTCOMES?

All patients will be provided with an initial survey pack, which will include:

- Information sheet with an opt-out consent form
- Preference for future surveys to be provided electronically (web-form) or paper form
- Patient reported outcome surveys for patients to complete (EORTC QLQ C30 and CR29)
- Comorbidity questionnaire to also be completed by the patient

Follow-up surveys at 6 months, and then annually for five (5) years will be sent out electronically to patients (of course, the option of completing via paper form is also available).

WHEN WILL OUTCOME COLLECTION TAKE PLACE?

WHEN	WHAT	Wно	How	PROCESS FOR INCOMPLETE FORMS
Initial Appointment or on referral to Colorectal MDT	 EORTC C30 and CR29 Self-administered comorbidity questionnaire 	Patient	Paper surveys will be sent out by the Outcome Measurement Coordinator following confirmation of diagnosis at the Colorectal MDT	Clinician to provide survey pack to patient. Outcome Measurement Coordinator will follow-up with electronic reminder after 1 month
At the first appointment following completion of treatment	Short Term Complications	Surgeon	Web-form (Figure 1) or email to project email address	Outcome Measurement Coordinator will follow-up with reminder to surgeon's private rooms after 2 weeks
		Radiation Oncologist	MoSAIQ (Figure 2)	Outcome Measurement Coordinator will follow-up with Radiation Oncologist after 2 weeks
		Medical Oncologist	MoSAIQ (Figure 2)	Outcome Measurement Coordinator will follow-up with Radiation Oncologist after 2 weeks
6 months	EORTC C30 and CR29	Patient	Electronic	Outcome Measurement Coordinator will send electronic surveys to patients (where requested)
12 months and annually to 5 years	EORTC C30 and CR29	Patient	Electronic	Outcome Measurement Coordinator will send electronic surveys to patients (where requested)
	Survival & Disease Control: Document local / regional / distant recurrence	Surgeon / Medical/Radiation Oncologist	Through follow-up consults in public / private rooms. Include ISLHD Cancer Care in all follow07p consult correspondence	Clinical Data Manager to follow-up missing data and maintain Rectal Cancer database

- See Appendix 1 for Outcome Measures Timeline
- See Appendix 2 for Summary of Measures
- See Appendix 3 for Follow-up protocol: colon and rectal cancer

ISLHD-RectalCancerOutcomes DT19/14153 31/01/2019

FIGURE 1: HOW SURGEONS ACCESS STC FORMS VIA ISLHD INTERNET


http://www.islhd.health.nsw.gov.au/

Our Services — Cancer and Haematology Network for Health Professionals



FIGURE 2: HOW ONCOLOGISTS ACCESS STC FORMS VIA MOSAIQ

eChart ---- Assessments ---- Allied Health/CNC --- Rectal Short Comp CTx (or RTx) --- Add



WHERE TO SEND PAPER-BASED SURVEYS / QUESTIONNAIRES?

Please Scan and Send to:

ISLHD-RectalCancerOutcomes@health.nsw.gov.au

NEED HELP?

Outcome collections and documentation can be found on the Colorectal MDT website

OR


Please do not hesitate to contact the Outcome Measures Project Coordinator at

ISLHD-RectalCancerOutcomes@health.nsw.gov.au

VERSION CONTROL

I	Version	DATE	OFFICER	DESIGNATION
	1	July 2018	Brooke Selby	Project Officer
	2	Jan 2019	Kathryn Mulligan	Cancer Systems Innovation Manager
Ī				

APPENDIX 1: OUTCOME MEASURES COLLECTION TIMELINE



^{*} At the first appointment following completion of surgery, chemotherapy or radiotherapy

ISLHD-RectalCancerOutcomes DT19/14153 31/1/2019

^{**} Medical and Radiation Oncology STC can be completed electronically via MoSAIQ

APPENDIX 2: SUMMARY OF MEASURES


Survival & Disease Control:	
Overall Survival	
Recurrence-free survival	
Progression-free survival	
Pathological complete response / tumour regression score	
Margin status	
Quirke score	

Degree of Health – Patient Reported Measures:				
Overall wellbeing	Fatigue	Gastrointestinal symptoms		
Emotional wellbeing	Mobility	Sexual functioning		
Social functioning	Bowel functioning	Erectile dysfunction		
Depression	Faecal leakage	Vaginal symptoms		
Physical functioning	Stool frequency	Presence of stoma (colostomy or ileostomy)		
Pain	Diarrhoea			


DISUTILITY OF CARE – SHORT TERM COMPLICATIONS OF TREATMENT						
RADIATION THERAPY	Снемотнекару	Surgery				
Skin desquamation	Febrile neutropenia	Anastomotic leak				
Dysuria	Mucositis (oral)	Stoma-related complications				
Diarrhoea	Acneiform rash	Incontinence post-op				
Proctitis	Hand-foot syndrome	Wound complications				
Mucositis	Neuropathy (sensory)	Thromboembolic event				
Weight loss	Diarrhoea	Haematoma				
Missed treatment	Dose reduction	Death within 30 days				
Incomplete treatment	Missed / delayed cycle	Blood transfusion				
Early cessation of concurrent chemotherapy	Incomplete treatment	Return to theatre				
	Unplanned ICU stay					
Intended to quantify impacts of therapy complications.	LOS > 21 days					
	Readmission < 30 days					

Follow-up protocol: colon and rectal cancer






- * Time period: from surgery if disease-free; from CT scan if recurrence or disease progression
- ** Subsequent colonoscopy interval: if normal at 1-year post-surgery, repeat 5-yearly; adenomas- repeat as per adenoma chart; cancer- refer as appropriate.
- *** CT scanning for stage I patients: not included in recommended routine follow-up in NCCN and Ontario guidelines up to discretion of clinician.



Follow-up protocol: colon and rectal cancer





- * Time period: taken from first treatment, then resets after second treatment; from CT scan if recurrence or disease progression
- ** Subsequent colonoscopy interval: if normal at 1-year post-surgery, repeat 5-yearly; adenomas- repeat as per adenoma chart; cancer- refer as appropriate.

Follow-up protocol: references



- 1. National Comprehensive Cancer Network (NCCN), 2017. Clinical practice guidelines in oncology: colon cancer, version 2
- 2. National Comprehensive Cancer Network (NCCN), 2017. Clinical practice guidelines in oncology: rectal cancer, version 3
- 3. Cancer Care Ontario, 2013. Colorectal cancer follow-up care patient pathway, version 2013.5
- 4. National Institute for Health Care Excellence (NICE), 2016. Surveillance report 2016 colorectal cancer (2011) NICE guidelines CG131 and improving outcomes in colorectal cancer (2004) NICE cancer service guidance CSG5
- 5. European Society for Medical Oncology (ESMO), Guidelines Working Group, Rectal Cancer, 2013. Clinical practice guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*; 24 (Supplement 6): vi81-vi88.
- 6. Rafferty J, et al. for the clinical practice guidelines committee of the American Society of Colon and Rectal Surgeons, 2015. Practice guideline for the surveillance of patients after curative treatment of colon and rectal cancer, *Disease of the colon & rectum*, 58: 713-725.
- 7. Australian Cancer Survivorship Centre, Peter MacCallum Cancer Centre, Follow-up of colorectal cancer survivors.
- 8. Cancer Council Australia Surveillance Colonoscopy Guidelines Working Party, 2013. Colonoscopic surveillance intervals following surgery for colorectal cancer, available at: http://wiki.cancer.org.au/australiawiki/images/3/34/Algorithm_for_Colonoscopic_Surveillance_Intervals_-
 Following Surgery for Colorectal Cancer.pdf# ga=2.21517435.1573391509.1500852300-1776091702.1498187560
- 9. Cancer Council Australia, 2017 *Clinical practice guidelines for the prevention, early detection and management of colorectal cancer* (DRAFT for consultation), Wiki guideline.

Note: This protocol contains evidence-based recommendations for follow-up, but should be tailored to individual patient needs

ISLHD-RectalCancerOutcomes DT19/14153 31/1/2019